Publications by authors named "Rafael Duarte Paes"
Article Synopsis
- The study explores challenges in lung cancer biomarker testing due to tissue inadequacy and operational issues, implementing a tailored molecular testing approach in Brazil.
- From 1,272 lung cancer samples analyzed, a significant percentage were ineligible for testing due to insufficient tissue quality or quantity, with specific mutations and alterations being most commonly observed.
- Results suggest that while non-NGS tests provided some diagnostic information, a substantial portion of patients could only access reduced molecular testing coverage, impacting the detection of actionable cancer drivers.
Introduction: Cancer patients with Covid-19 are exposed to treatment combinations that can potentially result in interactions that adversely affect patient outcomes. This study aimed to identify potential drug-drug interactions between antineoplastic agents and medicines used to treat Covid-19.
Methods: We conducted a search for potential interactions between 201 antineoplastic agents and 26 medicines used to treat Covid-19 on the Lexicomp and Micromedex databases.
Purpose: The COVID-19 pandemic remains a public health emergency of global concern. Determinants of mortality in the general population are now clear, but specific data on patients with cancer remain limited, particularly in Latin America.
Materials And Methods: A longitudinal multicenter cohort study of patients with cancer and confirmed COVID-19 from Oncoclínicas community oncology practice in Brazil was conducted.
Melanoma is the most aggressive form of skin cancer and until recently, it was extremely resistant to radio-, immuno-, and chemotherapy. Despite the latest success of BRAF V600E-targeted therapies, responses are typically short lived and relapse is all but certain. Furthermore, a percentage (40%) of melanoma cells is BRAF wild type.
View Article and Find Full Text PDF